Inclusion Criteria:

• - IPF diagnosis based upon American Thoracic Association, Japanese Respiratory Society, European Respiratory Society, Latin American Thoracic Association guidelines within the last 7 years.

Diagnosis will be confirmed to be consistent with IPF by centrally read high resolution computed tomography (HRCT).

• - Ability to successfully perform lung function tests.

• - Subjects are willing to remain on study treatment for the duration of the study.

• - Subjects have a full understanding of the informed consent.

Exclusion Criteria:

• - Evidence of other known causes of interstitial lung disease (ILD) (e.g., domestic, and occupational environmental exposures, connective tissue disease [CTD], and drug toxicity), lung transplant expected within 12 months of screening or evidence of clinically significant lung disease other than IPF including but not limited to asthma, chronic obstructive pulmonary disease (COPD), uncontrolled pulmonary hypertension and emphysema where computed tomography (CT)-assessed extent of emphysema is greater than extent of fibrosis.

• - History of malignancy, including carcinoma during the preceding 5 years.

With the following exceptions: 1. Prior history of in situ basal or squamous cell skin cancer that was successfully treated with curative therapies. 2. Subjects with other malignancies if they have been continuously disease free for at least 5 years prior to study start. 3. Subjects with prostate cancer that are managed by surveillance are also eligible.

• - Current use of supplemental oxygen for any condition unless prior approval is received from the Sponsor.

• - Smoking within 6 months of study start, current smoker, or unwillingness to refrain from smoking during the clinical trial duration.

• - Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).

• - Occurrence of serious illness requiring hospitalization within 90 days prior to study start.

• - Current or previous use (within 30 days prior to study start) of the following: 1.

N-acetylcysteine. 2. endothelin receptor antagonist. 3. riociguat. 4. prostacyclin or prostacyclin analogue. 5. Warfarin for IPF. 6. Cytotoxic agents (e.g., colchicine if used for IPF) 7. Radiation to the lungs. 8. Pulmonary rehabilitation. 9. Investigational agent for IPF. 10. Immunosuppressive medications (e.g., methotrexate, azathioprine) 11. Systemic or inhaled glucocorticosteroids. 12. Antifibrotic therapy (e.g., nintedanib, pirfenidone)

• - Regular use of phosphodiesterase type-5 inhibitor, occasional use for erectile dysfunction will be allowed.

• - Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start.

• - Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose.

• - Females that are pregnant or nursing.

• - Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose.

• - Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose.

• - Subjects with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.

• - Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.

Arms

Experimental: ENV-101

taladegib, 200 mg tablet, once daily for 12 weeks

Placebo Comparator: placebo

placebo, tablet, once daily for 12 weeks

Interventions

Drug: - taladegib

hedgehog pathway inhibitor dosed once daily

Drug: - placebo

identical tablets to the experimental arm with no active ingredient